Clinical profile of patients with metastatic colorectal adenocarcinoma treated with bevacizumab in first-line: AVATRAN study

15119 Background: Since the approval of Bevacizumab (Bev) for its use in the first line setting of metastatic colorectal cancer (mCRC) treatment, it has become one of the standard drugs used in first line combinations. To date there are no markers to identify patients (pts) that can most benefit from this drug, moreover, data from clinical trials indicate that almost every patient can benefit from this drug so, the decision whether to use it or not in a particular patient, is taken on an individual basis, patient by patient. We have analysed the clinical profile of pts treated with Bev all over Spain to identify the more common clinical profiles of pts selected by the physicians as the more suitable to receive Bev. Methods: This is an observational study carried out in 88 spanish centers. 280 patients have been included. Eligibility criteria: pts with mCRC that were being treated with a combination including Bev in first line in the common clinical practice. Primary end point was to describe the clinical ...